Form 4: Serina Therapeutics Director Steven Mintz Acquires Shares

Director Steven Mintz reports purchasing 6,000 shares of Serina Therapeutics at an average price of $6.469 on September 12, 2024.

Summary

• On September 12, 2024, Steven Mintz, a director of Serina Therapeutics, acquired 6,000 shares of common stock at a weighted average price of $6.469 per share.
• Following the transaction, Mintz directly owns 17,443 shares.
• Mintz also has indirect ownership through his spouse (12,257 shares) and three adult children (3,040, 2,840, and 2,650 shares respectively).
• Mintz disclaims beneficial ownership of the shares held by his spouse and children, except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the purchase is relatively small and could be for a variety of reasons.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders (officers, directors, and 10% owners) buy or sell their company's stock. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates